

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

-----X	:
In re Application of:	:
<b>Bandarpalle B. Shankar, <i>et al.</i></b>	:
For Patent For:	:
<b>"Cannabinoid Receptor Ligands"</b>	:
Serial No.: <b>10/803,577</b>	:
Filing Date: <b>03/18/2004</b>	:
-----X	:

Examiner: Z. N. Davis  
Group Art Unit: 1625  
Date: July 24, 2007

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450  
Mail Stop: **AMENDMENT**

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Sir:


It is requested that the documents listed on the accompanying PTO/SB/08B Form be considered and made of record in the above-identified patent application. Copies of the cited documents are attached.

No fee is believed to be due, however, if any fee is due the Commissioner is authorized to charge Deposit Account Number 19-0365 for any fees deemed necessary for consideration and entry of this Information Disclosure Statement into the file record.

Dated: July 24, 2007

Schering-Plough Corporation  
2000 Galloping Hill Road  
Kenilworth, NJ 07033  
Tel.: (908) 298-5734

Respectfully submitted,

  
\_\_\_\_\_  
Keith MacMillan  
Reg. No. 47,212  
Attorney of Record  
Telephone No.: (908) 298-5734

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

SUBSTITUTE FOR FORM 1449/PTO		ATTY. DOCKET NO.: IN06009US01	SERIAL NO.: 10/803,577
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (USE AS MANY SHEETS AS NECESSARY) SHEET <u>1</u> OF <u>1</u>		APPLICANT: Bandarpalle B. Shankar et al.	
		FILING DATE: 03/18/2004	GROUP: 1625
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
Examiner initials*	Cite no.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
DI	BELL, CRAIG H., et al.,	"The Chemistry of Arylelead(IV) Tricarboxylates. Reaction with Aromatics to Give Biaryls", Aust. J. Chem., (1979) pp. 1531-1550, Vol. 32.	
DJ	D'AMBRA, THOMAS E., et al.,	"C-Attached Aminoalkylindoles: Potent Cannabinoid Mimetics", Bioorganic & Medicinal Chemistry Letters, (1996), pp. 17-22, Vol. 6, No. 1.	
DK	FELDER, CHRISTIAN C., et al.,	"LY320135, a Novel Cannabinoid CB1 Receptor Antagonist, Unmasks Coupling of the CB1 Receptor to Stimulation of cAMP Accumulation", The Journal of Pharmacology and Experimental Therapeutics, (1998), pp. 291-297, Vol. 284, No. 1.	
DL	GALLANT, MICHEL, et al.,	"New Class of Potent Ligands for the Human Peripheral Cannabinoid Receptor", Bioorganic & Medicinal Chemistry Letters, (1996), pp. 2263-2268, Vol. 6, No. 19.	
DM	GENSLER, WALTER J., et al.,	"Reaction Pathway for the Formation of 3,3-Diphenyl-1-benzenesulfonamidopropane in the Aluminum Chloride Catalyst Reaction of 1-Benzenesulfonyl-2-(bromomethyl)ethylenimine and Benzene", J. Org. Chem., (1981), pp. 4051-4057, Vol. 46, No. 20.	
DN	LAN, RUOXI, et al.,	"Structure-Activity Relationships of Pyrazole Derivatives as Cannabinoid Receptor Antagonists", J. Med. Chem., (1999), pp. 769-776, Vol. 42.	
DO	OSMAN, A.M., et al.,	"Synthesis and Some Reactions of Naphth[1,2-d]oxazole-5-sulfonic Acids", J. Heterocyclic Chem., (1982), pp. 953-956, Vol. 19.	
DP	ROSS, RUTH A., et al.,	"Agonist-Inverse agonist characterization at CB <sub>1</sub> and CB <sub>2</sub> cannabinoid receptors of L759633, L759656 and AM630", British Journal of Pharmacology, (1999), pp. 665-672, Vol. 126.	
DQ	SHIM, JOONG-YOUN, et al.,	"Three-Dimensional Quantitative Structure-Activity Relationship Study of the Cannabimimetic (Aminoalkyl)indoles Using Comparative Molecular Field Analysis", J. Med. Chem., (1998), pp. 4521-4532, Vol. 41, No. 23.	
DR	English translation of First Office Action (PCT application entering into the national phase) Chinese Patent Application No. 200480007295.X, issued February 2, 2007.		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.